FDA Amends OTC Oral Sodium Phosphate Labeling, Warns Of Risks
This article was originally published in The Tan Sheet
Executive Summary
FDA recommends consumers not use OTC oral sodium phosphate for bowel cleansing and says it will amend labeling for the products because of a risk of serious kidney injuries
You may also be interested in...
In Brief
FDA proposes laxative monograph change
FDA’s Agenda Slates September For Cough/Cold Proposal, Sunscreen Rule
Meeting deadlines on regulatory agenda actions, such as finalizing OTC monographs, could be a higher priority for FDA under its new management
FDA Nonprescription Office Adding Staff To Focus On Monograph Work
FDA's Division of Nonprescription Regulation Development will hire additional staff to accelerate monograph work and enhance the office's internal expertise